Iovance Biotherapeutics Inc

2026-09-16 19:03; UTC

Iovance Biotherapeutics reported record second-quarter revenue of nearly $100 million and is preparing for multiple data updates, driving shares higher since Tuesday.

2026-09-15 23:01; UTC

Iovance Biotherapeutics is higher in after-market hours, reflecting broader market gains. No specific company news was identified to explain the movement.

2026-09-14 20:08; UTC

Iovance Biotherapeutics shares are rising amid discussions of a potential valuation at $16, reflecting levels seen in early 2021. The stock is above its 20-day moving average.

2026-09-11 19:16; UTC

Iovance Biotherapeutics is gaining amid social media discussions about an upcoming conference, with expectations for quarterly revenue exceeding $100 million.

2026-09-10 23:06; UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours. The stock has seen three consecutive lower daily finishes despite recent strength over the past month.

2026-09-09 20:07; UTC

Iovance Biotherapeutics Inc shares are lower amid broader market declines, with no specific news identified to explain today's volatility.

2026-09-04 19:46; UTC

Iovance Biotherapeutics shares are higher as the company announces participation in two upcoming healthcare conferences to discuss advancements in TIL therapies.

2026-09-03 23:51; UTC

Iovance Biotherapeutics Inc shares are higher in after-market trading, maintaining a position above its 20-day moving average amid broader market gains.

2026-09-02 19:16; UTC

Iovance Biotherapeutics is up today, continuing a trend of three consecutive higher daily closes despite rising global bond yields and no specific news.

2026-09-01 23:06; UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours, reflecting a slight decline since Tuesday's close amid rising oil prices and inflation concerns.

2026-08-31 19:36; UTC

Iovance Biotherapeutics shares are lower amid increased interest rate hike expectations and uncertainties regarding its product execution and approvals.

2026-08-28 23:11; UTC

Iovance Biotherapeutics Inc is trading higher in after-market hours, remaining near the upper end of its one-month range and above its 20-day moving average.

2026-08-27 23:01; UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours amid a broader market decline influenced by recent economic data and Fed policy expectations.

2026-08-26 23:46; UTC

Iovance Biotherapeutics is trading higher in after-market hours, showing unusual activity and remaining above its 20-day moving average. No specific news was identified.

2026-08-25 19:16; UTC

TD Cowen maintained a Buy rating on Iovance Biotherapeutics and raised its price target to $10, contributing to the stock's gains since Monday.

2026-08-24 23:26; UTC

Iovance Biotherapeutics shares are higher in after-market trading, continuing an upward trajectory since Monday's close, despite recent declines over three sessions.

2026-08-21 20:02; UTC

Iovance Biotherapeutics is lower in Friday's session, with no specific news identified. The broader market also remains down significantly since Thursday's close.

2026-08-20 23:06; UTC

Iovance Biotherapeutics reached a 52-week high after UBS raised its target price to $7, noting strong second-quarter sales of $91 million.

2026-08-19 23:16; UTC

Iovance Biotherapeutics shares reached a new 52-week high amid positive melanoma treatment sector sentiment and an anticipated revenue guidance increase.

2026-08-18 23:06; UTC

Iovance Biotherapeutics shares were roughly flat in after-market hours. The broader market faced pressure from rising bond yields and increased oil prices.

2026-08-17 19:36; UTC

Iovance Biotherapeutics reaches a new 52-week high above $7 amid positive results from the IOV-LUN-202 trial for metastatic NSCLC.

2026-08-14 23:26; UTC

Iovance Biotherapeutics Inc. gains in after-market trading, reaching a 52-week high above $7 amid positive sentiment for IOV-LUN-202 and upcoming updates.

2026-08-13 19:21; UTC

Iovance Biotherapeutics Inc shares are lower today, reaching a midday low after earlier gains. No specific news was identified to explain the decline.

2026-08-12 19:16; UTC

Iovance Biotherapeutics Inc shares rise amid positive social media discussions and analyst projections of over $400 million in revenue this year.

2026-08-11 23:46; UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours amid volatility. No specific news was identified to explain the price movement.

2026-08-10 23:56; UTC

Iovance Biotherapeutics reported second-quarter revenue of $99.3 million, a 66% increase, contributing to a rise in shares during after-market hours.

2026-08-07 20:03; UTC

Iovance Biotherapeutics rises as Barclays and Citizens raise price targets amid positive sentiment and high trading volume.

2026-08-06 20:03; UTC

Iovance Biotherapeutics reported record Q2 revenue of $99.3 million, exceeding estimates. The stock is higher amid strong demand and FDA Fast Track Designation for SAR-201.

2026-08-05 23:16; UTC

Iovance Biotherapeutics shares are higher in after-market trading, reflecting broader market strength amid falling crude oil prices and strong corporate earnings.

2026-08-04 19:51; UTC

Iovance Biotherapeutics is rising amid broader market strength from falling crude oil prices and positive economic data, despite lingering inflation concerns.